Medicine Classification Updates




9 AUGUST 2007

NEW ZEALAND GAZETTE, No. 89

2313

Pyridoxal; in medicines containing more than 200 milligrams per recommended daily dose
Pyridoxamine; in medicines containing more than 200 milligrams per recommended daily dose
Rasagilin
Riluzole
Rimexolone
Rimonabant
Ruboxistaurin
Sabadilla
Schoenocoulon officinale
Scopolia carniolica
Sitagliptin
Sorafenib
Sumatriptan; except when specified elsewhere in the Schedule
Sunitinib
Telbivudine
Thenyldiamine
Tipepidine
Tolpropamine
Trimeprazine; except when specified elsewhere in the Schedule
Triprolidine; except when specified elsewhere in the Schedule
Varenicline
Vildagliptin

Schedule 2

Restricted Medicines

Azatadine; for oral use in adults and children over two years of age

Azelastine; in medicines for ophthalmic use containing 0.05% or less

Brompheniramine; for oral use in medicines for adults and children over two years of age except when specified elsewhere in the Schedule

Chlorpheniramine; for oral use in medicines for adults and children over two years of age except when specified elsewhere in the Schedule

Dexchlorpheniramine; for oral use in medicines for adults and children over two years of age except when specified elsewhere in the Schedule

Dimenhydrinate; for oral use in medicines for adults and children over two years of age except when specified elsewhere in the Schedule

Diphenhydramine; for oral use in medicines for adults and children over two years of age except when specified elsewhere in the Schedule

Diphenylpyraline; for oral use in medicines for adults and children over two years of age except when specified elsewhere in the Schedule

Doxylamine; for oral use in medicines for adults and children over two years of age except when specified elsewhere in the Schedule

Hydrocortisone and hydrocortisone acetate but no other esters of hydrocortisone; for dermal use in medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base with no other ingredient except an antifungal and in a quantity of 30 grams or less or 30 millilitres or less per container; in rectal medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of 35 grams or less per container or up to 12 suppositories per pack.

*Ibuprofen; for oral use in tablets or capsules containing up to 400 milligrams per dose form and in packs containing not more than 50 dose units which have received the consent of the Minister or the Director-General to their distribution as restricted medicines and are sold in the manufacturer’s original pack

Levonorgestrel; in medicines for use as emergency post-coital contraception when in packs containing not more than 1.5 milligrams except when sold by nurses recognised by their professional body as having competency in the field of sexual and reproductive health

Mepyramine; for oral use in medicines for adults and children over two years of age

Oxiconazole; for vaginal use

Promethazine; for oral use in medicines for adults and children over two years of age except when specified elsewhere in the Schedule

Salicylic acid; except in medicines for dermal use containing 40% or less

*Sumatriptan; for oral use in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms when in tablets containing 50 milligrams or less per tablet and when sold in a pack containing not more than two tablets which has received the consent of the Minister or the Director-General to its sale as a restricted medicine

Trimeprazine; for oral use in medicines for adults and children over two years of age

Triprolidine; for oral use in medicines for adults and children over two years of age except when specified elsewhere in the Schedule

Schedule 3

Pharmacy-only Medicines

*Beclomethasone; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine

Brompheniramine; for oral use in medicines for adults or children over two years of age when combined in the same container with one or more other therapeutically active substances either when in the bedtime dose of a day-night pack containing brompheniramine or when at least one of the other therapeutically active substances is a sympathomimetic decongestant

*Budesonide; for the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age when in aqueous nasal sprays delivering up to 50 micrograms per actuation and when the maximum recommended daily dose is no greater than 400 micrograms and the medicine has received the consent of the Minister or the Director-General to its distribution as a pharmacy-only medicine

Chlorpheniramine; for oral use in medicines for adults and children over two years of age when combined in the same container with one or more other therapeutically active substances either when in the bedtime dose of a day-night pack containing chlorpheniramine or when at least one of the other therapeutically active substances is a sympathomimetic decongestant

Dexchlorpheniramine; for oral use in medicines for adults and children over two years of age when combined in the same container with one or more other therapeutically active substances either when in the bedtime dose of a



Next Page →



Online Sources for this page:

VUW Te Waharoa PDF NZ Gazette 2007, No 89


Gazette.govt.nz PDF NZ Gazette 2007, No 89





✨ LLM interpretation of page content

🏥 Classification of Medicines (continued from previous page)

🏥 Health & Social Welfare
Medicines, Classification, Prescription, Restricted, Pharmacy-only